0
0.5
1
1.5
2+
Mortality
67%
Improvement
Relative Risk
Ventilation
80%
ICU admission
91%
Hospitalization
81%
Hospitalization (b)
86%
primary
Sotrovimab Gupta et al. EARLY TREATMENT DB RCT
Is early treatment with sotrovimab beneficial for COVID-19?
Double-blind RCT 583 patients in the USA (August 2020 - March 2021)
Lower hospitalization with sotrovimab (p=0.00071)
c19early.org
Gupta et al., NEJM, May 2021
Favors sotrovimab
Favors control